BOURLA ALBERT 4

What Happened

• Albert Bourla, Chairman & CEO and a director of Pfizer Inc., was reported as acquiring 22 units (each representing one phantom share) on April 30, 2026. The units were valued at $26.70 each for a total reported value of $587. This transaction is recorded as an award/acquisition (A) — not an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-04-30 — 22 units @ $26.70 each (total $587).
• Filing date: Form 4 filed 2026-05-04 (within the standard two business-day reporting window).
• Shares/units after transaction: The filing reports the 22 phantom-share units acquired; total holdings after the grant are not specified in the summary information provided.
• Footnotes: F1 — each unit equals one phantom share of common stock; F2 — units were acquired under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan, are cash-settled upon separation from service, and may be transferred by the reporting person into an alternative investment account at any time.

Context

• These are phantom (non-equity) units that are cash-settled rather than actual common stock. Such deferred-compensation awards are common and do not represent an immediate purchase of tradable shares; they typically reflect compensation deferral rather than a direct market signal.